Jaris,
Just keep in mind that the mice studies showed greater lifespan from the higher dosage. We want to inhibit mTOR as much as possible, but not too much.
The elderly volunteers were all 65+ years of age, and they tolerated it very well. Here are the results posted in that study on the amount of inhibition at the doses given for the study.
In the intent-to-treat population, the low-dose RAD001 (0.5 mg daily or
5 mg weekly) cohorts, but not the higher-dose (20 mg weekly) cohort, met
the primary endpoint of the study (Fig. 1A). Modeling and simulation
based on mTOR-mediated phosphorylation of its downstream target S6
kinase (S6K) predicted that the 20 mg weekly dosing regimen inhibited
mTOR-mediated S6K phosphorylation almost completely, the 5 mg weekly
dosing regimen inhibited S6K phosphorylation by more than 50%, and the
0.5 mg daily dosing regimen inhibited S6K phosphorylation by about 38%
over the dosing interval (12). Thus, partial inhibition of mTOR-mediated
S6K phosphorylation achieved with a relatively low dose of RAD001 may
be as effective as nearly complete inhibition associated with high-dose
RAD001 at enhancing the immune response of the elderly volunteers.
Keeping in mind that a larger dose does mean a longer lifespan, as far as we know at this point. My personal sweet spot is 6-9 mg once a week to achieve 75-85% S6K phosphorylation inhibition. If you get side effects back off, keeping in mind everyone's metabolism is different. The intermediate dosing schedule of once weekly should keep most side effects at bay.